

We claim:

1. A multispecific binder comprising:
 - 5 (a) an immunoglobulin single variable domain (ISVD) that binds to programmed cell death protein 1 (PD1) comprising
a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 3 or SEQ ID NO: 6; a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 4 wherein X is W or V or SEQ ID NO: 7 wherein X is W or V; and
10 a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 5 wherein X is W or F; and
(b) an ISVD that binds to lymphocyte activation gene 3 (LAG3) comprising:
a CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 65 or amino acids 6-10 of SEQ ID NO: 65; a CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66 or
15 amino acids 1-10 of SEQ ID NO: 66; and a CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 67.
2. The multispecific binder of claim 1, wherein the ISVD that binds to PD1 comprises the amino acid sequence set forth in SEQ ID NO: 1 or 2 wherein the sequence comprises a mutation
20 at residue 11 and/ or 89 and optionally a substitution of the Asp at position 1 with a Glu; wherein said residue numbers are Kabat residue numbers.
3. The multispecific binder of claim 1, wherein the ISVD that binds to PD1 comprises the amino acid sequence:
25 DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREVAV ITWSGGITYY
ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYG QGTLVTVSS
(SEQ ID NO: 57, or said sequence optionally comprising a D1E mutation);
EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREVAVITWSGGITYYADSVKGRFTISRDNKNT
VYLQMNSLRPEDTAIYYCAGDKHQSSWYDYGQGTLVTVSS
30 (SEQ ID NO: 98, or said sequence optionally comprising a E1D mutation);
EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREVAVITWSGGITYYADSVKGRFTISRDNKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYGQGTLVTVSS
(SEQ ID NO: 99, or said sequence optionally comprising a E1D mutation);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYWGQGLTVTVSS

(SEQ ID NO: 103, or said sequence optionally comprising a D1E and/or N73S mutation);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISR DQSKNT
5 VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS

(SEQ ID NO: 104, or said sequence optionally comprising a D1E mutation); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISR DPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS

(SEQ ID NO: 105, or said sequence optionally comprising a D1E mutation); or

10 DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISR DPSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS (amino acids 1-119 of SEQ ID NO: 113, or
said sequence optionally comprising a D1E mutation); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISR DQSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS (amino acids 1-119 of SEQ ID NO: 117, or

15 said sequence optionally comprising a D1E mutation); or

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSGGITYYADSVKGRFTISR DSSKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYWGQGLTVTVSS (amino acids 1-119 of SEQ ID NO: 121, or
said sequence optionally comprising a D1E mutation).

4. The multispecific binder of claim 1, wherein the ISVD that binds LAG3 comprises the
20 amino acid sequence set forth in SEQ ID NO: 64 or SEQ ID NO: 64 comprising a substitution of
the Asp at position 1 with a Glu.

5. The multispecific binder of claim 1, wherein the multispecific binder further includes an
ISVD that binds to human serum albumin comprising CDR1 comprising the amino acid sequence
25 set forth in SEQ ID NO: 60 or amino acids 1-5 of SEQ ID NO: 60; CDR2 comprising the amino
acid sequence set forth in SEQ ID NO: 61 or amino acids 1-10 of SEQ ID NO: 61; and CDR3
comprising the amino acid sequence set forth in SEQ ID NO: 62.

6. A multispecific binder comprising:
30 (a) an immunoglobulin single variable domain (ISVD) that binds to programmed
cell death protein 1 (PD1) comprising: a CDR1 comprising the amino acid sequence I_HAMG (SEQ
ID NO: 3) or G_{SI}ASIHAMG (SEQ ID NO: 6); a CDR2 comprising the amino acid sequence
VITXSGGITYYADSVKG (SEQ ID NO: 4; wherein X is W or V) or VITXSGGITY (SEQ ID NO: 7;

wherein X is W or V); and a CDR3 comprising the amino acid sequence DKHQSSXYDY (SEQ ID NO: 5, wherein X is W or F); and

(b) an immunoglobulin single variable domain that binds to lymphocyte activation gene 3 (LAG3) comprising: a CDR1 comprising the amino acid sequence GRTFSDYVMG (SEQ ID NO: 65) or DYVMG (amino acids 6-10 of SEQ ID NO: 65); a CDR2 comprising the amino acid sequence AISESGGRTHYADSVKG (SEQ ID NO: 66) or AISESGGRTH (amino acids 1-10 of SEQ ID NO: 66); and a CDR3 comprising the amino acid sequence TLLWWTSEYAPIKANDYDY (SEQ ID NO: 67); and,

(c) a half-life extender and a C-terminal extender.

7. The multispecific binder of claim 6, wherein

(a) the immunoglobulin single variable domain that binds to PD1 comprises the amino acid sequence

DVQLVESGGG VVQPGGSLRL SCAASGSIAS IHAMGWFRQA PGKEREFVAV ITWSSGITYY

ADSVKGRFTI SRDNSKNTVY LQMNSLRPED TALYYCAGDK HQSSWYDYG QGTLVTVSS

(SEQ ID NO: 57);

EVQLVESGGGLVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSSGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYGQGTLVTVSS

(SEQ ID NO: 98);

EVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSSGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYGQGTLVTVSS

(SEQ ID NO: 99);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITWSSGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSWYDYGQGTLVTVSS

(amino acids 1-119 of SEQ ID NO: 101);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSSGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYGQGTLVTVSS

(SEQ ID NO: 103);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSSGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYGQGTLVTVSS

(SEQ ID NO: 104);

DVQLVESGGGVVQPGGSLRLSCAASGSIASIHAMGWFRQAPGKEREFVAVITVSSGITYYADSVKGRFTISRDN SKNT
VYLQMNSLRPEDTALYYCAGDKHQSSFYDYGQGTLVTVSS

(SEQ ID NO: 105); and,

(b) the immunoglobulin single variable domain that binds to LAG3 comprises the amino acid sequence

EVQLVE SGGGVVQPGG SLRLSCAASG RTFSDYVMGW FRQAPGKERE FVAAISESGG RTHYADSVKG
RFTISRDN SK NTLYLQMNSL RPEDTALYYC ATTLLWWTSE YAPIKANDYD YWGQGTLLTV SS

5 (SEQ ID NO: 64); or

DVQLVESGGGVVQPGGSLRLSCAASGR TFSYVMGWFRQAPGKEREFVAAISESGGRTHYADSVKGRFTISRDN SKNT
LYLQMNSLRPEDTALYYCAT TLLWWTSEYAPIKANDYDYWGQGTLLTVSS

(amino acids 1-128 of SEQ ID NO: 96).

10 8. The multispecific binder of claim 6, wherein the C-terminal extender is an alanine.

9. The multispecific binder of any one of claim 6, wherein the multispecific binder comprises:

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- 15 • a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 98;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 20 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 63;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- 25 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- 30 • a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;

- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- 5 • a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- 10 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- 15 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 99;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- 20 • a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9 GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

25 or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 30 • a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and

- a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- 5 • a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 20GS linker comprising the amino acid sequence set forth in SEQ ID NO: 100;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

or,

- 10 • a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 57;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- 15 • a C-terminal Alanine;

or

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (wherein
- 20 the Asp at position 1 is replaced with a Glu);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- 25 • a C-terminal Alanine;

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105 (wherein
- 30 the Asp at position 1 is substituted with a Glu);

- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - 5 • a C-terminal Alanine;
- or
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - 10 • a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine;
- or,
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 105;
 - 15 • a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine;
- 20 or,
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (wherein
the Asp at position 1 is replaced with a Glu);
 - 25 • a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine;
- 30 or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104 (wherein the Asp at position 1 is replaced with a Glu);
- 5
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine;
- 10 or,
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- 15
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine;
- or,
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 104;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- 20
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
 - a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
 - a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
 - a C-terminal Alanine
- or
- 25
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
 - a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
 - a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asp at position 1 is replaced with Glu and the Asn at position 73 is replaced with Ser);
- 30
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;

- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

5 or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asp at position 1 is replaced with Glu and the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

15

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and
- a C-terminal Alanine;

20

or,

- a PD1 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 103 (wherein the Asn at position 73 is replaced with Ser);
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a LAG3 ISVD comprising the amino acid sequence set forth in SEQ ID NO: 64;
- a 9GS linker comprising the amino acid sequence set forth in SEQ ID NO: 125;
- a HSA ISVD comprising the amino acid sequence set forth in SEQ ID NO: 59; and

30

- a C-terminal Alanine

wherein said residue numbers are Kabat residue numbers.

10. The multispecific binder of claim 6, wherein the multispecific binder comprises the amino acid sequence set forth in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123 or 124.

11. The multispecific binder of claim 6, wherein the multispecific binder binds to PD1 and LAG3.

12. The multispecific binder of claim 6, wherein the half-life extender is a human serum albumin ISVD that binds to human serum albumin comprising:

CDR1 comprising the amino acid sequence `GFTFSSFGMS` (SEQ ID NO: 60) or `SFGMS` (amino acids 1-5 of SEQ ID NO: 60);

CDR2 comprising the amino acid sequence `SISGSGSDTLYADSVKG` (SEQ ID NO: 61) or `SISGSGSDTL` (amino acids 1-10 of SEQ ID NO: 61); and

CDR3 comprising the amino acid sequence `GGSLSR` (SEQ ID NO: 62).

13. The multispecific binder of claim 12 wherein the ISVD that binds human serum albumin comprises the amino acid sequence

`EVQLVESGGG VVQPGNSLR L SCAASGFTFS SFGMSWVRQA PGKGLEWVSS ISGSGSDTLYADSVKGRFTI SRDNAKTTLY LQMNSLRPED TALYYCTIGG SLRSSQGT L VTVSSA`
(SEQ ID NO: 59).

14. A multispecific binder that cross-blocks a multispecific binder of claim 6 from binding to LAG3 or PD1 and LAG3.

15. An injection device or vessel that comprises the multispecific binder of claim 6, optionally in association with a further therapeutic agent.

16. A composition comprising a multispecific binder of claim 6 and at least one pharmaceutically acceptable carrier, diluent or excipient.

17. The composition of claim 16, wherein the multispecific binder comprises the amino acid sequence set forth in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, or 124.

18. The composition of claim 17, wherein the multispecific binder comprises the amino acid sequence set forth in SEQ ID NO: 110.

19. A multispecific binder consisting of the amino acid set forth in SEQ ID NO: 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, or 124.

20. A composition comprising the multispecific binder of claim 19 and at least one pharmaceutically acceptable carrier, diluent or excipient.

21. A multispecific binder consisting of the amino acid set forth in SEQ ID NO: 110.

22. A composition comprising the multispecific binder of claim 21 and at least one pharmaceutically acceptable carrier, diluent or excipient.

23. A multispecific binder comprising a programmed cell death protein 1 (PD1) binder having the amino acid sequence set forth in SEQ ID NO: 57 and a lymphocyte activation gene 3 (LAG3) binder having the amino acid sequence set forth in SEQ ID NO: 64.

24. The multispecific binder of claim 23, wherein the multispecific binder further comprises a human serum albumin (HSA) binder having the amino acid sequence set forth in SEQ ID NO: 59.

25. A multispecific binder comprising an N-terminal immunoglobulin single variable domain (ISVD) that binds programmed cell death protein 1 (PD1) comprising the amino acid sequence set forth in SEQ ID NO: 57; an ISVD that binds lymphocyte activation gene 3 (LAG3)

comprising the amino acid sequence set forth in SEQ ID NO: 64; an ISVD that binds human serum albumin (HSA) comprising the amino acid sequence set forth in SEQ ID NO: 59; and a C-terminal Alanine.

- 5 26. A multispecific binder comprising an N-terminal immunoglobulin single variable domain (ISVD) that binds programmed cell death protein 1 (PD1) comprising the amino acid sequence set forth in SEQ ID NO: 57; a 35GS linker comprising the amino acid sequence set forth in SEQ ID NO: 58; an ISVD that binds lymphocyte activation gene 3 (LAG3) comprising the amino acid sequence set forth in SEQ ID NO: 64; a 35GS linker comprising the amino acid sequence set
10 forth in SEQ ID NO: 58; an ISVD that binds human serum albumin (HSA) comprising the amino acid sequence set forth in SEQ ID NO: 59; and a C-terminal Alanine.

27. A composition comprising the multispecific binder of claim 24 and at least one pharmaceutically acceptable carrier, diluent or excipient.

15

28. A multispecific binder comprising the amino acid set forth in SEQ ID NO: 110.